Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

NewsGuard 100/100 Score
Nov 8 2010

Jasco Pharmaceuticals, LLC was awarded a grant under the US Government's Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma's novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

“We are excited to receive the grant in recognition that our innovative Pim inhibitor program shows promise to bring forward a novel oncology therapeutic”

"We are excited to receive the grant in recognition that our innovative Pim inhibitor program shows promise to bring forward a novel oncology therapeutic," said Carmen Baldino, president of Jasco Pharmaceuticals, "This funding will assist in accelerating the development of our program."

Source:

 Jasco Pharmaceuticals

Posted in: Medical Condition News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Breakthrough imaging method enhances precision in prostate cancer treatment
Study links air pollution to increased colorectal cancer risk through DNA changes
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
DASH diet may lower the risk of cardiovascular disease in breast cancer survivors
MONET: New AI tool enhances medical imaging with deep learning and text analysis
New Lancet Commission on Breast Cancer: Transforming breast cancer care globally
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
New trials show promise for immune checkpoint blockers in early-stage lung cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels